Theralase Technologies Inc. (CVE:TLT - Get Free Report) reached a new 52-week high on Monday . The company traded as high as C$2.18 and last traded at C$0.21, with a volume of 49500 shares trading hands. The stock had previously closed at C$0.20.
Theralase Technologies Stock Up 2.8%
The stock has a 50-day simple moving average of C$0.19 and a two-hundred day simple moving average of C$0.22. The company has a quick ratio of 3.40, a current ratio of 1.91 and a debt-to-equity ratio of 14.85. The firm has a market cap of C$45.05 million, a PE ratio of -9.85 and a beta of 1.36.
About Theralase Technologies
(
Get Free Report)
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Recommended Stories
Before you consider Theralase Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theralase Technologies wasn't on the list.
While Theralase Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
